文章：

弥漫性大B细胞淋巴瘤：新靶点与新型疗法

Diffuse large B-cell lymphoma: new targets and novel therapies

原文发布日期：2021-04-05

DOI: 10.1038/s41408-021-00456-w

类型: Review Article

开放获取: 是

英文摘要：

Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.
 

摘要翻译： 

对于弥漫性大B细胞淋巴瘤（DLBCL）及其他B细胞恶性肿瘤患者而言，更新、更有效且非细胞毒性的治疗方案仍是尚未得到满足的医疗需求。近期获批的药物包括泊洛妥珠单抗联合苯达莫司汀和利妥昔单抗、塞利尼索，以及他法西他单抗联合来那度胺。目前美国FDA已批准三种CAR-T细胞产品，另有多项产品处于临床试验阶段。正在研发的其他药物还包括双特异性抗体和抗体药物偶联物。靶向疗法的联合应用有望进一步改善B细胞恶性肿瘤患者的治疗结局。

原文链接：

Diffuse large B-cell lymphoma: new targets and novel therapies